Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 11/20 | 0.49 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384634 | 0.86 | TRPV4 (0.49) | CYP19A1HSD11B1TRPV4CYP3A4KCNH2 | |
| SCHEMBL5103723 | 0.84 | CYP19A1 (0.56) | TSHRHTTCYP19A1ALDH1A1TRPV4 | |
| SCHEMBL20003506 | 0.81 | CYP19A1 (0.60) | CYP19A1TRPV4CYP3A4KCNH2 | |
| SCHEMBL3333148 | 0.81 | TSHR (0.50) | TSHRCYP19A1ALDH1A1TRPV4CYP3A4 | |
| SCHEMBL13157386 | 0.79 | TSHR (0.46) | TSHRLMNAHPGDMAPK1HTT | |
| SCHEMBL2959205 | 0.79 | TRPV4 (0.50) | CYP19A1HSD11B1TRPV4CYP3A4KCNH2 | |
| SCHEMBL13993549 | 0.79 | MEN1 (0.69) | LMNAHTTHSD11B1ALDH1A1MCOLN3 | |
| SCHEMBL693259 | 0.78 | TSHR (0.51) | TSHRLMNAHPGDMAPK1HTT | |
| SCHEMBL15014519 | 0.77 | ALDH1A1 (0.63) | LMNAHTTHSD11B1ALDH1A1MCOLN3 | |
| SCHEMBL13108111 | 0.75 | TSHR (0.44) | TSHRLMNAHPGDMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | TSHR 1082/4885LMNA 1043/4885HPGD 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.